Generic Name and Formulations:
Japanese encephalitis virus vaccine; inactivated; aluminum hydroxide adsorbed; susp for IM inj; contains formaldehyde, protamine sulfate; preservative-free.
Novartis Pharmaceuticals Corp
Indications for IXIARO:
Japanese encephalitis immunization.
≥17yrs: Two doses given 28 days apart. Each dose is 0.5mL IM into deltoid muscle; complete series at least 1 week prior to potential exposure.
<17yrs: not recommended.
Severe allergic reaction (eg, anaphylaxis) after a previous dose.
Immunodeficiency. Bleeding disorders. Acute febrile illness. Allergy to protamine sulfate. Have epinephrine inj (1:1000) available. Pregnancy (Cat.B). Nursing mothers.
Concomitant vaccines: see literature. Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response.
Japanese encephalitis vaccine.
Local reactions (eg, pain, tenderness), headache, myalgia, fatigue, flu-like illness, GI upset, pyrexia.
Single-dose syringe (0.5mL)—1
Endocrinology Advisor Articles
- Soluble Klotho Levels Predictive of Kidney Failure in Type 2 Diabetes
- HbA1c Levels Predictive of Liraglutide Treatment Response in T2D
- Clinicians May Be Overtreating Older Patients With Diabetes
- Comorbid and Pharmacologic Factors Increase Risk for Gastrointestinal Disorders in Diabetes
- ADA Updates Guidelines for Cardiovascular Risk Management in Diabetes
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Hormonal Contraceptives May Adversely Affect Psychological Health in Adolescent Girls
- Obesity Can Negatively Effect Liver in Children as Young as 8
- Recommendations Developed on Gender Equity in Medicine
- Intensive Lifestyle Interventions Cut Long-Term Disability in Type 2 Diabetes